Current Takeaway
Vascular endothelial dysfunction and microcirculatory impairment remain a plausible core mechanism linking fatigue, orthostatic symptoms, cognitive strain, and post-exertional worsening in ME/CFS and Long COVID. The model is no longer limited to isolated microclot reports. Newer work is layering together capillary structure, cerebral perfusion responses, extracellular-vesicle signals, platelet and complement activation, and coagulation profiling into a broader thrombo-inflammatory picture.
The latest additions push the field toward multi-scale measurement rather than one single marker. Conference data from the MIRACLE program suggest that accessible tools such as capillaroscopy and orthostatic transcranial Doppler may capture microvascular and cerebral perfusion differences, while extracellular-vesicle cargo studies point to endothelial and hypoperfusion-related biomarker candidates. A new longitudinal multi-omics paper also strengthens the idea that acute immunothrombosis can leave a durable endothelial-platelet activation signature in people who later develop Long COVID.
Clinical translation is still early. A 2026 review on thromboelastography is useful because it frames clot strength and impaired fibrinolysis as measurable functional signals, but it is still a review rather than new cohort evidence. No blood-flow, microclot, or coagulation assay here is ready to serve as a standalone diagnostic or treatment guide, and intervention evidence remains preliminary.
Why This Matters
The identification of structural capillary alterations and circulating microclots shifts the understanding of post-infectious syndromes from subjective, descriptive conditions to defined, measurable endovascular diseases. Documenting physical barriers to oxygen transport—such as thickened basement membranes that hinder oxygen diffusion, narrowed vessel lumens, and stiffened red blood cells—provides a direct physiological explanation for the muscle oxygenation deficits and exercise intolerance observed in patient cohorts. Targeting these pathways opens concrete therapeutic options, including soluble guanylate cyclase stimulators to restore vasodilation, anti-NETosis agents or anticoagulants to address fibrinolysis-resistant microclots, and rheological treatments to enhance red blood cell deformability.
State of Evidence
- Established: ME/CFS and Long COVID research continues to show reproducible signs of vascular dysregulation, including impaired perfusion, endothelial stress, abnormal clotting biology, and links between these changes and symptom burden.
- Plausible but early: Multi-scale approaches are gaining traction, with nailfold capillaroscopy, orthostatic cerebral flow measurements, extracellular-vesicle cargo, endothelial-platelet transcriptomic programs, and thromboelastography all pointing toward thrombo-inflammatory perfusion problems. These signals are mechanistically coherent, but they are not yet standardized enough for routine use.
- Not established: It remains unclear whether microclots, endothelial injury, and platelet activation are primary disease drivers, downstream consequences, or only one branch of a broader multi-system process. TEG-guided management, anticoagulant strategies, and other clot-targeting interventions do not yet have robust controlled evidence in these populations.
- Key limitations: Several important additions are conference-stage findings, small female-only biomarker cohorts, or review-level syntheses. Assay standardization remains a major barrier, especially for microclot detection and real-time coagulation profiling.
Timeline
2024-09-06 - Review proposes multi-systemic model linking microvascular dysfunction to post-exertional malaise
A comprehensive narrative review synthesized existing evidence to construct a biological model for post-exertional malaise (PEM), linking microvascular dysfunction to cellular energy failure. The model posits that impaired microcirculation (including endothelial damage and fibrinolysis-resistant microclots) restricts muscle perfusion, forcing a premature switch to anaerobic metabolism during minimal physical activity. This metabolic shift leads to an accumulation of lactate and reactive oxygen species, triggering immune activation and secondary tissue damage in a self-propagating feedback loop. This model establishes a multi-systemic framework that moves clinical focus toward investigating endothelial function and perfusion-targeted interventions like L-arginine. However, the review does not generate new clinical or experimental data, and it does not prove that all described pathophysiological features coexist in every patient.
Sources:
2025-03-21 - Blood transcriptomics identify altered erythrocyte gene expression in male subgroup
A transcriptomic study of peripheral blood cells from 54 Post-COVID Condition (PCC) patients and controls revealed that persistent symptoms are generally not reflected by major shifts in global blood gene expression. However, subgroup analysis identified a distinct male cohort showing significant changes in 399 genes and an increased proportion of immature red blood cells (erythroblasts) in circulation. These altered genes are primarily involved in heme metabolism and red blood cell gas exchange processes. This finding points to oxygen transport and erythrocyte health as a patient-specific disease driver, reinforcing the biological heterogeneity of post-infectious conditions. The study does not prove that these transcriptomic alterations directly cause symptoms of fatigue or exercise intolerance, nor does it clarify why this signature is limited to male patients.
Sources:
2025-04-01 - Thigh muscle biopsies reveal structural capillary narrowing and basement membrane thickening
A comparative analysis of skeletal muscle biopsies (vastus lateralis) from ME/CFS and Long COVID patients revealed severe structural pathology in the microvasculature. Under advanced microscopy, patient capillaries showed significantly thickened basement membranes and increased collagen IV deposition, resulting in a narrowed lumen radius. Furthermore, patients with ME/CFS exhibited a reduced capillary density (fewer capillaries per muscle fiber) compared to healthy controls, which correlated with impaired muscle oxygenation during exercise measured via near-infrared spectroscopy (NIRS). This provides direct physical evidence of anatomical barriers to oxygen diffusion and nutrient exchange within skeletal muscle tissue, explaining peripheral exertional intolerance. The findings do not prove the upstream mechanism driving the basement membrane thickening, nor do they demonstrate whether these structural capillary changes are reversible.
Sources:
2025-08-11 - Microfluidic velocity assays reveal impaired red blood cell response to low oxygen
An ex vivo study using capillary-mimicking microfluidic devices demonstrated that red blood cells (RBCs) from ME/CFS patients have an impaired velocity response to hypoxic stress. Unlike healthy RBCs, which speed up as oxygen tension () decreases to maintain tissue perfusion, patient-derived RBCs showed a significantly reduced acceleration response. Measuring this dynamic “velocity slope” distinguished patients from controls with 77.8% accuracy and 90% specificity, demonstrating its potential as an objective diagnostic biomarker. Additionally, ex vivo treatment of patient RBCs with salmeterol xinafoate or xanomeline restored the velocity response to low oxygen. The study does not prove that these pharmaceutical agents will show safety or efficacy in clinical trials, nor does it establish the exact intracellular mechanism impairing RBC deformability and movement.
Sources:
2025-10-15 - Circulating microclots in Long COVID are stabilized by neutrophil extracellular traps
A comparative imaging study of blood plasma using imaging flow cytometry found that circulating microclots are nearly 20 times more abundant and significantly larger in Long COVID patients compared to controls. The research demonstrated that neutrophil extracellular traps (NETs)—sticky webs of DNA released by activated neutrophils—are physically embedded within these microclots, serving as a structural scaffold. This structural integration makes the microclots highly resistant to natural enzymatic breakdown (fibrinolysis), explaining their persistence in circulation. Combining microclot and NET markers achieved a diagnostic accuracy of 91%, supporting a thrombo-inflammatory model of disease. The study does not establish whether NET-stabilized microclots are a primary driver of tissue hypoxia or a secondary biomarker, nor does it prove that therapies targeting both fibrin and DNA structures are clinically effective.
Sources:
2025-11-26 - SARS-CoV-2 Spike protein fragments directly trigger lysis-resistant amyloid microclots
An in vitro laboratory study demonstrated that specific amyloidogenic fragments of the SARS-CoV-2 Spike protein, particularly Spike685, directly interact with the human coagulation system to impair fibrinolysis. Co-incubation of purified clotting proteins with these Spike fragments resulted in the formation of dense, abnormal amyloid-like fibrin clot networks. These Spike-induced clot networks were structurally resistant to enzymatic degradation (lysis) by tissue plasminogen activator (tPA). This provides a direct molecular explanation for the persistence of fibrin amyloid microclots (fibrinaloids) in post-viral syndromes, linking persistent viral antigens to chronic vascular pathology. The study does not prove that these specific Spike fragments are present in the circulation of all patients, nor does it replicate the complex cellular environments of blood vessels in vivo.
Sources:
2025-12-25 - Soluble guanylate cyclase stimulation shows potential for treating chronic vascular dysfunction
A patent and associated Phase 2a clinical trial (VERI-LONG/VERI-ME) involving 104 participants evaluated the soluble guanylate cyclase (sGC) activator vericiguat to treat chronic vascular impairment. The therapeutic approach is based on the hypothesis that stimulating the sGC/cGMP pathway restores blood vessel dilation, breaking the cycle of low perfusion, tissue hypoxia, and mitochondrial damage. Titrated administration of the sGC stimulator improved microvascular perfusion and physical function (measured by SF-36) and was generally well-tolerated. This represents a significant shift from observational biomarkers to targeted pharmacological intervention designed to improve nitric oxide bioavailability. However, these Phase 2a results represent preliminary efficacy in a cohort restricted to ages 18 to 50, and larger phase 3 trials are necessary to confirm clinical benefit and establish safety profiles.
Sources:
2026-01-25 - Retinal vessel analysis documents systemic microvascular remodeling and endothelial dysfunction
A prospective, multi-cohort study utilizing Retinal Vessel Analysis (RVA) demonstrated significant structural and functional impairment in the microcirculation of patients with ME/CFS and Post-COVID Syndrome (PCS). Patients showed narrower retinal arterioles and a severely reduced ability of these vessels to dilate in response to flicker-light stimulation, with ME/CFS patients exhibiting the most profound dysfunction. These vascular alterations correlated directly with neurocognitive symptom severity and matched markers of systemic inflammation (IL-6) and iron dysregulation. This establishes RVA as a non-invasive, objective in vivo marker of systemic endothelial dysfunction and thrombo-inflammatory vascular pathology. The study does not prove that retinal microvascular changes reflect identical pathology in other key organ systems, and the findings remain in preprint form awaiting peer review.
Sources:
2026-04-22 - Pediatric Long COVID study links microclots to Spike-induced neutrophil activation
An endovascular profiling study of 84 children and young adults (aged 25 and younger) demonstrated elevated levels of circulating microclots and markers of microvascular remodeling (such as FGF-2). The research showed that cell-free DNA—a marker of neutrophil extracellular traps (NETs)—was elevated in patients and directly triggered by Spike-containing immune complexes. This intravascular neutrophil activation (NETosis) strongly correlated with microclot severity and serum amyloid A levels, indicating a persistent inflammatory loop. This work extends the thrombo-inflammatory model of post-viral syndromes into the pediatric population, shifting focus toward objective endothelial biomarkers in young people. The study does not prove that neutralizing Spike-containing immune complexes or blocking NETosis will resolve clinical cardiovascular symptoms, and it is limited by a moderate sample size.
Sources:
2026-05-07 - MIRACLE sub-study reports early capillary and orthostatic cerebral perfusion differences in ME/CFS
At the International ME/CFS Conference 2026, Annabell Sprenger presented preliminary vascular findings from the MIRACLE collaborative study using nailfold capillaroscopy and transcranial Doppler during orthostatic stress. Baseline cerebral flow velocities did not clearly separate patients from controls, but after passive standing the ME/CFS group showed a consistent trend toward lower cerebral flow velocities, while controls maintained higher values. The capillaroscopy work also suggested possible sex-related differences and a relationship between capillary measures and functional status. This is useful because it tests practical bedside-style tools across both microvascular and macrovascular scales instead of relying on a single specialized lab assay. The evidence remains preliminary, with small analyzed subgroups and effect sizes that have not yet matured into statistically definitive diagnostic thresholds.
Sources:
2026-05-07 - Extracellular-vesicle cargo study links endothelial hypoperfusion signals to symptom severity
Also at the International ME/CFS Conference 2026, Martina Seifert presented extracellular-vesicle profiling from female post-COVID ME/CFS, other post-infectious ME/CFS, and control groups. Basic vesicle size and concentration were not markedly different, but cargo analysis identified altered proteins and lower EV-derived hsa-let-7b-5p in post-COVID ME/CFS, with lower levels correlating with worse fatigue, pain, immune symptoms, and physical functioning. The project also framed these vesicle findings within broader endothelial and glycocalyx injury mechanisms involving autoantibodies, NETs, and prothrombotic factors. This matters because it offers a possible bridge between symptom severity and endothelial signaling rather than treating hypoperfusion as purely structural. It is still early biomarker work from small female cohorts and does not yet establish disease specificity.
Sources:
2026-06-11 - Longitudinal multi-omics ties acute immunothrombosis to persistent endothelial-platelet activation in Long COVID
Ansone and colleagues followed 81 hospitalized COVID-19 patients from the acute phase into recovery and compared those who later developed Long COVID with those who recovered. Acute illness showed the expected immunothrombotic pattern, including complement activation, neutrophil and NET-related programs, platelet activation, mitochondrial metabolic stress, and renal tubular injury. What makes the study important for this thread is that at 3 months, the Long COVID group still showed a distinct blood signature consistent with endothelial-associated and platelet activation, including elevated VWF and PROS1 transcripts alongside inflammatory and tissue-remodeling signals. That supports the idea that acute thrombo-inflammatory injury can leave a durable vascular imprint rather than resolving cleanly once infection clears. The study still reflects a hospitalized severe-COVID population, so it should not be assumed to map directly onto every ME/CFS or community Long COVID cohort.
Sources: